福元医药：参与国家组织集采药品协议期满品种接续采购拟中选

Core Viewpoint - The company, Fuyuan Pharmaceutical (601089.SH), participated in a national procurement process for drugs whose agreements have expired, with some of its products expected to be selected in the upcoming procurement results [1] Group 1: Procurement Details - The company attended the national organized procurement for drugs with expired agreements on February 9, 2026 [1] - The results of the procurement are expected to be implemented by the end of March 2026, with provincial medical institutions beginning to sign procurement contracts based on the selected results [1] Group 2: Market Impact - Although the sales prices of the selected drugs are expected to decrease, the company aims to stabilize its existing market share [1] - The company is positioned to potentially increase its market share due to its brand influence and reliable supply capabilities, which may positively impact its future operating performance [1]